How rigorous research built a $US141bn company, Moderna

Moderna co-founder Robert Langer says vaccine development for a range of diseases – not just Covid-19 – will be one of the biggest trends among biotechnology in coming years.

Jared Lynch

How rigorous research built a $US141bn company, Moderna

October 27, 2021
Moderna co-founder Robert Langer says vaccine development for a range of diseases – not just Covid-19 – will be one of the biggest trends among biotechnology in coming years.
Read Transcript

Having launched more than a dozen biotech companies, including mRNA vaccine producer Moderna, the question Robert Langer gets asked the most is “what is the next big thing”.

After all, investing in biotechs is not for the faint of heart. For every unicorn that emerges there are scores that fall over in clinical trials. But Dr Langer has a knack of knowing what works, with his 3 per cent stake in Moderna catapulting him into the billionaires’ club.

Since it listed on the Nasdaq in 2018, Moderna’s value has soared from $US7.5bn to $US141bn ($188bn), largely thanks to it developing a highly effective vaccine against Covid-19.

But long before the pandemic, Dr Langer knew he was onto a winner with Moderna, a portmanteau of mode and RNA.

“I’m not surprised that it’s successful,” Dr Langer said ahead of speaking at the Sohn Hearts & Minds investor conference.

“I mean back in 2010 when we started, I remember coming home and telling my wife this was going to be the most successful biotech company ever. I just felt that the right elements – the right technology, the right people involved.”

But none of it would have happened without decades of rigorous research into messenger RNA technology, which instructs the body’s cells to make a protein that triggers an immune response against diseases such as Covid-19.

Dr Langer is quick to highlight this grunt work and the importance of R & D when people approach him at conferences and other events, asking “what will be the next big thing”.

“My answer is that it hasn‘t been invented yet,” he said.

“It is really important to support basic research, so that people can invent the things of the future that don‘t exist. That’s the most common question people always ask – what’s going to be the big thing in the next five years?

“Of course it depends whether you’re talking about something clinical or something that can be transformative like messenger RNA or nanotechnology or CRISPRs and things like that.”

Still, many biotechs are aiming to capture that next big thing, whether it was the race to develop a Covid vaccine or developing a treatment for a rare disease. Before a biotech embarks on clinical trials, the blue sky potential appears endless, only to end up in heartache when things don’t go to plan.

Even established players like Australia’s biggest health company CSL has had some misses, like its homegrown Covid-19 vaccine it was developing with the University of Queensland which it aborted after trials revealed it triggered false positives for HIV.

So what’s Dr Langer’s secret in picking what flies?

“Well, I guess if I were to pick a formula, it is to take a really transforming scientific idea, that would be number one, but that’s also like what I call platform technology, meaning you could use it over and over again, for different things, different diseases for example or different types of drugs.

“That’s validated by in vivo data and by excellent scientific papers. In fact, one thing investors ought to look and see where some of the seminal papers that lead to that company are published. Are they published in top journals like Science or Nature, or not? And that they have very good intellectual property, that they have excellent business people, that they have excellent investors, that would be my general area.”

For the near term, a spotlight is going to be cast on vaccination – and not just for Covid-19, which most health experts are expecting will be part of our lives for decades, requiring booster shots and research into more next generation vaccines to combat challenges such as cold chain storage.

“What you’ll see is more and more vaccines being produced. We will see, at some point, better ways of delivering them to patients. And you'll certainly see a lot of vaccines based on our messenger RNA for other diseases,” Dr Langer said.

“If you look at the Moderna pipeline, there’s about nine different diseases that we're studying for vaccines.”

These include therapeutic vaccines for cancer as well as prophylactic vaccines to build immunity against viruses like Covid.

And the main thing that Dr Langer is focused on is his connection to lab work.

“The major thing I still do is run my academic lab. To me it’s a team effort. My students want see their doctoral work or postdoctoral work lead to products that could help people and I want to see that happen too.

“It’s really been a team effort I’ve had the good fortune of working with some excellent investors, excellent CEOs. The science part I can help a lot with but I’ve had the good fortune of working with very good people in the other areas and that’s been key.”

And in his lab could be the next big thing. About 150 people in his team are working on a range of projects from a single-step method – meaning all its takes is one dose to inoculate someone against a disease for life – pills that only need to be taken once a week, a month or even a year; and children’s nutrition.

“We’re working on new children’s pills. We’re also working on new ways of giving nutrition. There’s about 2 billion children or people that are malnourished, we’re working on ways of also delivering nutrients much better to people,” Dr Langer said.

“And then the other giant area that we work on in our lab we started many years ago called tissue engineering, which is ways of making new tissues and organs from scratch. That’s actually led to skin for burn victims, there are clinical trials for making new blood vessels and there are other clinical trials for spinal cord repair, hearing loss. So there are all kinds of things you could do.”

The 2021 Sohn Hearts & Minds Conference will be held on December 3. Tickets and details at sohnheartsandminds.com.au

 

The article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

 

Having launched more than a dozen biotech companies, including mRNA vaccine producer Moderna, the question Robert Langer gets asked the most is “what is the next big thing”.

After all, investing in biotechs is not for the faint of heart. For every unicorn that emerges there are scores that fall over in clinical trials. But Dr Langer has a knack of knowing what works, with his 3 per cent stake in Moderna catapulting him into the billionaires’ club.

Since it listed on the Nasdaq in 2018, Moderna’s value has soared from $US7.5bn to $US141bn ($188bn), largely thanks to it developing a highly effective vaccine against Covid-19.

But long before the pandemic, Dr Langer knew he was onto a winner with Moderna, a portmanteau of mode and RNA.

“I’m not surprised that it’s successful,” Dr Langer said ahead of speaking at the Sohn Hearts & Minds investor conference.

“I mean back in 2010 when we started, I remember coming home and telling my wife this was going to be the most successful biotech company ever. I just felt that the right elements – the right technology, the right people involved.”

But none of it would have happened without decades of rigorous research into messenger RNA technology, which instructs the body’s cells to make a protein that triggers an immune response against diseases such as Covid-19.

Dr Langer is quick to highlight this grunt work and the importance of R & D when people approach him at conferences and other events, asking “what will be the next big thing”.

“My answer is that it hasn‘t been invented yet,” he said.

“It is really important to support basic research, so that people can invent the things of the future that don‘t exist. That’s the most common question people always ask – what’s going to be the big thing in the next five years?

“Of course it depends whether you’re talking about something clinical or something that can be transformative like messenger RNA or nanotechnology or CRISPRs and things like that.”

Still, many biotechs are aiming to capture that next big thing, whether it was the race to develop a Covid vaccine or developing a treatment for a rare disease. Before a biotech embarks on clinical trials, the blue sky potential appears endless, only to end up in heartache when things don’t go to plan.

Even established players like Australia’s biggest health company CSL has had some misses, like its homegrown Covid-19 vaccine it was developing with the University of Queensland which it aborted after trials revealed it triggered false positives for HIV.

So what’s Dr Langer’s secret in picking what flies?

“Well, I guess if I were to pick a formula, it is to take a really transforming scientific idea, that would be number one, but that’s also like what I call platform technology, meaning you could use it over and over again, for different things, different diseases for example or different types of drugs.

“That’s validated by in vivo data and by excellent scientific papers. In fact, one thing investors ought to look and see where some of the seminal papers that lead to that company are published. Are they published in top journals like Science or Nature, or not? And that they have very good intellectual property, that they have excellent business people, that they have excellent investors, that would be my general area.”

For the near term, a spotlight is going to be cast on vaccination – and not just for Covid-19, which most health experts are expecting will be part of our lives for decades, requiring booster shots and research into more next generation vaccines to combat challenges such as cold chain storage.

“What you’ll see is more and more vaccines being produced. We will see, at some point, better ways of delivering them to patients. And you'll certainly see a lot of vaccines based on our messenger RNA for other diseases,” Dr Langer said.

“If you look at the Moderna pipeline, there’s about nine different diseases that we're studying for vaccines.”

These include therapeutic vaccines for cancer as well as prophylactic vaccines to build immunity against viruses like Covid.

And the main thing that Dr Langer is focused on is his connection to lab work.

“The major thing I still do is run my academic lab. To me it’s a team effort. My students want see their doctoral work or postdoctoral work lead to products that could help people and I want to see that happen too.

“It’s really been a team effort I’ve had the good fortune of working with some excellent investors, excellent CEOs. The science part I can help a lot with but I’ve had the good fortune of working with very good people in the other areas and that’s been key.”

And in his lab could be the next big thing. About 150 people in his team are working on a range of projects from a single-step method – meaning all its takes is one dose to inoculate someone against a disease for life – pills that only need to be taken once a week, a month or even a year; and children’s nutrition.

“We’re working on new children’s pills. We’re also working on new ways of giving nutrition. There’s about 2 billion children or people that are malnourished, we’re working on ways of also delivering nutrients much better to people,” Dr Langer said.

“And then the other giant area that we work on in our lab we started many years ago called tissue engineering, which is ways of making new tissues and organs from scratch. That’s actually led to skin for burn victims, there are clinical trials for making new blood vessels and there are other clinical trials for spinal cord repair, hearing loss. So there are all kinds of things you could do.”

The 2021 Sohn Hearts & Minds Conference will be held on December 3. Tickets and details at sohnheartsandminds.com.au

 

The article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

 

Disclaimer: This material has been prepared by The Australian, published on Oct 27, 2021. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
November 2, 2023

Meet the 2023 Conference Managers

Following a rigorous global search, the Conference Fund Manager Selection Committee is pleased to share ten new managers for 2023.

Read More
Daniel Loeb oversees $US11.7 billion ($18.5 billion) at New York-based Third Point. Picture: BloombergDaniel Loeb oversees $US11.7 billion ($18.5 billion) at New York-based Third Point. Picture: BloombergDaniel Loeb oversees $US11.7 billion ($18.5 billion) at New York-based Third Point. Picture: BloombergDaniel Loeb oversees $US11.7 billion ($18.5 billion) at New York-based Third Point. Picture: Bloomberg
October 23, 2023

Dan Loeb to headline Sohn Hearts & Minds

Famed hedge fund manager Dan Loeb has been named as one of the headline acts for next month’s Sohn Hearts & Minds philanthropic investment conference to be held in Sydney.

Read More
Ravi Chopra's Azora Capital had its best month in March when it shorted the US banks that failed. Picture: Jaclyn LichtRavi Chopra's Azora Capital had its best month in March when it shorted the US banks that failed. Picture: Jaclyn LichtRavi Chopra's Azora Capital had its best month in March when it shorted the US banks that failed. Picture: Jaclyn LichtRavi Chopra's Azora Capital had its best month in March when it shorted the US banks that failed. Picture: Jaclyn Licht
October 23, 2023

US Bank Run Has Slowed To A Walk, But Instability Remains

When Ravi Chopra reveals his stock pick at the prestigious Sohn Hearts & Minds conference at the Opera House in Sydney next month, it could well be a short bet on a US bank.

Read More
October 18, 2023

Two small caps: Propel Funeral Services (ASX: PFP) and Clarity Pharmaceuticals (ASX: CU6)

Get to know our 2023 Conference Fund Manager Rikki Bannan of IFM Investors who recently featured on the Equity Mates Media podcast.

Read More
October 16, 2023

How this hedge fund pulled off 2023’s ‘big short’

Last year, Ravi Chopra was travelling through Europe to shop his latest short idea to potential investors. “Financials are really all in the weeds,” he told The Australian Financial Review in an interview from New York.

Read More
IFM Investors executive director Rikki Bannan is a keen follower of stocks in the healthcare sector, but she knows it can be a risky place to invest.IFM Investors executive director Rikki Bannan is a keen follower of stocks in the healthcare sector, but she knows it can be a risky place to invest.IFM Investors executive director Rikki Bannan is a keen follower of stocks in the healthcare sector, but she knows it can be a risky place to invest.IFM Investors executive director Rikki Bannan is a keen follower of stocks in the healthcare sector, but she knows it can be a risky place to invest.
October 10, 2023

Beware the pitfalls of investing in healthcare, says IFM boss

“Healthcare is often viewed as a stable, defensive sector to invest in, but in small caps that hasn’t necessarily proven to be the case,” she says in an interview ahead of her appearance at the Sohn Hearts & Minds Conference 2023.

Read More
October 6, 2023

Secret to a long life cheaper than you think celebrity physician Peter Attia reveals

Don't miss Dr Peter Attia who will speak at the Sohn Hearts & Minds Conference at the Sydney Opera House next month.

Read More
Angela Aldrich of Bayberry Capital Partners in New York. Picture: Jaclyn Licht.Angela Aldrich of Bayberry Capital Partners in New York. Picture: Jaclyn Licht.Angela Aldrich of Bayberry Capital Partners in New York. Picture: Jaclyn Licht.Angela Aldrich of Bayberry Capital Partners in New York. Picture: Jaclyn Licht.
September 18, 2023

‘Volatility is opportunity’: why this manager loves shorting stocks

Angela Aldrich of Bayberry Capital Partners LP bet against Treasury Wine Estates at the top of the market and now she's preparing to make her next big call at this year's Sohn Hearts & Minds Conference.

Read More
September 15, 2023

Top fund managers share 11 stock picks for the long term

After a dramatic earnings season, fund managers, including Jessica Farr-Jones of Regal Funds and Kieran Moore of Munro Partners (HM1 Core Fund Managers), have shared some of their top picks for long-term growth.

Read More
September 11, 2023

Investors Sweeten On Hedge Funds As Rates Climb

After a decade of easy money pushing equity markets in one direction, Wall Street hedge fund manager Ricky Sandler says the return of volatility and higher interest rates is seeing money return to long-short strategies.

Read More
Eminence Capital CEO Ricky Sandler, left, with Sohn Australia co-founder Matthew Grounds. Picture: John FederEminence Capital CEO Ricky Sandler, left, with Sohn Australia co-founder Matthew Grounds. Picture: John FederEminence Capital CEO Ricky Sandler, left, with Sohn Australia co-founder Matthew Grounds. Picture: John FederEminence Capital CEO Ricky Sandler, left, with Sohn Australia co-founder Matthew Grounds. Picture: John Feder
September 11, 2023

Stock Stars Look Under The Surface

Influential New York-hedge fund manager Ricky Sandler returns to Australia to make a new pick at this year’s Sohn Hearts & Minds conference that will be held at the Sydney Opera House on November 17.

Read More
Barrenjoey co-executive chairman Matthew Grounds and New York-based Eminence Capital fund manager Ricky Sandler will be at the eighth Sohn Hearts & Minds conference. Picture: Peter RaeBarrenjoey co-executive chairman Matthew Grounds and New York-based Eminence Capital fund manager Ricky Sandler will be at the eighth Sohn Hearts & Minds conference. Picture: Peter RaeBarrenjoey co-executive chairman Matthew Grounds and New York-based Eminence Capital fund manager Ricky Sandler will be at the eighth Sohn Hearts & Minds conference. Picture: Peter RaeBarrenjoey co-executive chairman Matthew Grounds and New York-based Eminence Capital fund manager Ricky Sandler will be at the eighth Sohn Hearts & Minds conference. Picture: Peter Rae
September 11, 2023

Top Ny Stock Picker Warns Inflation To Remain Above Pre-Covid Levels

Influential New York hedge fund manager Ricky Sandler of Eminence Capital returns for the 2023 Sohn Hearts & Minds Conference in Sydney and says no one is focused on picking interesting, idiosyncratic stocks.

Read More
August 4, 2023

New Relic

New Relic was pitched by Ricky Sandler of Eminence Capital at the 2022 Sohn Hearts & Minds Conference.

Read More
June 18, 2023

Investors can’t agree how to value the world’s hottest stock

Despite mixed investor opinions, Munro Partners (Core Fund Manager) remains a strong believer in Nvidia. They are standing firm in their investment and still consider it a solid buy.

Read More
June 8, 2023

Stock pickers bet the field in slowing domestic market

Fund managers have batted away fears of an inflation-led recession, with Qantas, Seven Group and Treasury Wines named among the best investments by Australia’s top stock pickers.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.